Market Access Changes to UK’s VPAG: Non-submissions should be a key metric... Whatever people think of changes to the UK’s pricing deal, VPAG, judging the difference they make should include monitoring non-submissions to NICE.
News AbbVie turbocharges its US investment promise to $100bn AbbVie finally agrees a Most-Favoured Nation pricing deal with the US administration, with a $100 billion investment promise attached.
News J&J jumps on the MFN pricing train Johnson & Johnson is the latest pharma group to agree a Most-Favoured Nation (MFN) drug pricing deal with the Trump administration to avert tariffs.
News Court blocks HHS' 340B rebate programme pilot Hospitals that challenged a US pilot of a new rebate model for medicines provided to low-income people have won another legal victory.
News Judge blocks HHS' 340B rebate pilot at 11th hour A federal judge in the US has granted a restraining order that will stop the 340B rebate model from launching as planned on 1st January.
Patients Rethinking prescription drug affordability, with Vinay Patel Vinay Patel, an innovative pharmacist, discuss the intricacies of drug pricing and accessibility in the US.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.